Search

Displaying results 1511 - 1520 of 6198 in total
  1. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain [L3263]. … Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263]

  2. Drug

    Glipizide

    go.drugbank.com/drugs/DB01067
    ApprovedInvestigational

    Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. … According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin.

  3. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    Etuvetidigene autotemcel is an autologous gene therapy which includes hematopoietic stem cells (HSCs) that have been genetically modified ex vivo. … [L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system.

  4. Drug

    Etoricoxib

    go.drugbank.com/drugs/DB01628
    ApprovedInvestigationalWithdrawn

    It is approved in more than 60 countries worldwide but not in the US.

  5. Drug

    Rose bengal

    go.drugbank.com/drugs/DB11182
    ApprovedInvestigational

    Rose bengal is a pink stain derived as an analogue of fluorescein. Its disodium salt in ophthalmic solutions has been used as a diagnostic agent in suspected damage to conjunctival and corneal cells.

  6. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody. … -, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

  7. Drug

    Amoxapine

    go.drugbank.com/drugs/DB00543
    Approved

    They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. … The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission.

  8. Drug

    Eteplirsen

    go.drugbank.com/drugs/DB06014
    ApprovedInvestigational

    [A244930] It is caused by loss-of-function mutations in the DMD gene coding for dystrophin, an essential protein involved in maintaining the structural integrity and function of muscle fibres. … Eteplirsen was the first treatment for DMD approved by the FDA.[A244925]

  9. Drug

    Amikacin

    go.drugbank.com/drugs/DB00479
    ApprovedInvestigationalVet approved

    Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood. … [L4680] Several forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection.

    Products: AMIKACINA MK 250 MG/ML
  10. Drug

    Ambroxol

    go.drugbank.com/drugs/DB06742
    ApprovedInvestigational

    Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents. … It stimulates synthesis and release of surfactant by type II pneumocytes.

    Products: K-NOUL, AMBROXOL MK 30MG TABLETAS